Treatment of follicular lymphomas using inhibitors of the LT pathway
View Patent ↗Therapeutic uses of inhibitors of the lymphotoxin pathway to treat tumors, specifically to treat follicular lymphomas.
1. A method for arresting or reducing the advancement, severity or effects of a follicular lymphoma comprising the administration to a subject having a follicular lymphoma of an effective amount of an anti-LT-β antibody which inhibits the interaction between LT-β and its receptor.
2. The method of claim 1 , wherein the subject is a mammal.
3. The method of claim 2 , wherein the subject is a human.
4. The method according to claim 1 , wherein the antibody is a monoclonal antibody directed against LT-β.
5. The method of claim 4 , wherein the monoclonal antibody is humanized or chimeric.
6. The method of claim 1 comprising the administration to said subject of at least one chemotherapeutic agent.
7. The method of claim 1 further comprising the administration to said subject of an inhibitor of another TNF pathway.
8. The method of claim 7 comprising the administration of a composition which inhibits the CD40/CD40 ligand pathway.
9. The method of claim 8 comprising the administration of an anti-CD40 ligand antibody.
10. The method of claim 1 further comprising the administration to said subject of radiation treatments.
11. The method of claim 1 further comprising the administration to said subject of a bone marrow transplant.
12. The method of claim 1 , wherein the antibody is administered as a single dose.
13. The method of claim 1 , wherein the antibody is administered daily.
14. The method of claim 1 , wherein the antibody is administered every 2 to 6 days.
15. The method of claim 1 , wherein the antibody is administered weekly, biweekly or monthly.
16. The method of claim 6 , wherein the antibody which inhibits the interaction between LT-β and its receptor is administered prior to the administration of the chemotherapeutic agent.
17. The method of claim 12 , wherein the antibody which inhibits the interaction between LT-β and its receptor is administered simultaneously with the chemotherapeutic agent.
18. The method of claim 6 , wherein the antibody which inhibits the interaction between LT-β and its receptor is administered subsequent to the administration of the chemotherapeutic agent.
19. The method of claim 1 , wherein the antibody which inhibits the interaction between LT-β and its receptor further comprises a pharmaceutically acceptable carrier.